KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
139 hedge funds and large institutions have $616M invested in KalVista Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 55 increasing their positions, 31 reducing their positions, and 18 closing their positions.
1,091% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $1.04M
77% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 31
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
9% more funds holding
Funds holding: 128 → 139 (+11)
0.95% less ownership
Funds ownership: 110.46% → 109.51% (-0.95%)
4% less capital invested
Capital invested by funds: $640M → $616M (-$24.9M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$11.1M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.71M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.13M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.96M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$8.45M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$5.78M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$5.34M |
| 4 |
AI
Allostery Investments
Stamford,
Connecticut
|
-$5.11M |
| 5 |
JP Morgan Chase
New York
|
-$4.64M |
KALV Hedge Fund Activity: Q2 2025 in Review
139 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2025, worth a combined $616M — down 3.9% from $640M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new KALV positions and 18 closed out — a net gain of 12 holders — while 55 added to existing stakes and 31 trimmed.
The largest buyer was Ameriprise, adding an estimated $11.1M. The largest seller was Great Point Partners, cutting an estimated $8.45M.
- 139 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2025, up from 128 in Q1 2025.
- Funds reported $616M of KalVista Pharmaceuticals stock for Q2 2025, down 3.9% quarter-over-quarter.
- 30 funds opened new KalVista Pharmaceuticals positions in Q2 2025 and 18 closed out, a net change of +12 holders.
- The largest KalVista Pharmaceuticals buyer in Q2 2025 was Ameriprise, an estimated $11.1M added.
- The largest KalVista Pharmaceuticals seller in Q2 2025 was Great Point Partners, an estimated $8.45M sold.
Based on aggregated 13F filings for Q2 2025.